Sugi Predict

Sugi Predict / Compounds / SCHEMBL2371447

SCHEMBL2371447

SCHEMBL2371447

CN1CCN(c2ccc(CC(=O)O)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 4/20 0.63
▸ ITGA2B P08514 4/20 0.63
▸ NPC1 O15118 4/20 0.61
▸ RAB9A P51151 4/20 0.61
▸ CHKA P35790 1/20 0.57
▸ KLKB1 P03952 1/20 0.53
▸ CTSB P07858 1/20 0.53
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ POLB P06746 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ NSD2 O96028 1/20 0.50
▸ GRK2 P25098 1/20 0.50
▸ CASP6 P55212 1/20 0.50
▸ CTDSP1 Q9GZU7 1/20 0.50
▸ NCF1 P14598 1/20 0.50
▸ HDAC3 O15379 1/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370707 0.85 NPC1 (0.56) ITGB3ITGA2BNPC1RAB9ACHKA
SCHEMBL1065084 0.84 ITGB3 (0.64) ITGB3ITGA2BNPC1RAB9AKLKB1
SCHEMBL2285282 0.84 ITGB3 (0.64) ITGB3ITGA2BNPC1RAB9ACHKA
SCHEMBL20424995 0.83 GFER (0.61) ITGB3ITGA2BNPC1RAB9ALMNA
SCHEMBL10900400 0.83 GFER (0.66) ITGB3ITGA2BLMNASMN1; SMN2POLB
SCHEMBL5789032 0.82 CHKA (0.60) NPC1RAB9ACHKALMNATP53
SCHEMBL2282564 0.82 ITGB3 (0.62) ITGB3ITGA2BNPC1RAB9AKLKB1
SCHEMBL13855699 0.82 ITGB3 (0.62) ITGB3ITGA2BNPC1RAB9AKLKB1
SCHEMBL2370530 0.82 SMN1; SMN2 (0.60) NPC1RAB9ACHKALMNASMN1; SMN2
SCHEMBL23387331 0.81 ITGB3 (0.57) ITGB3ITGA2BNPC1RAB9AKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121586713-A Quinoline derivatives and pharmaceutical compositions thereof for the treatment of diseases 百济神州(苏州)生物科技有限公司 2026-02-27 — — CN disclosed
WO-2025021217-A1 QUINOLINE DERIVATIVES AND PHARMARCEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASE BEIGENE SWITZERLAND GMBH (CH) 2025-01-30 — — WO disclosed
CN-107474024-B Glutaminase inhibitor and composition and application thereof 北京赛林泰医药技术有限公司 2022-12-13 — — CN disclosed
EP-2668184-B1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT PF MEDICAMENT (FR) 2018-01-10 — — EP disclosed
EP-2877176-B1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK PF MEDICAMENT (FR) 2017-04-26 — — EP disclosed
EP-2877176-B1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK PF MEDICAMENT (FR) 2017-04-26 — — EP disclosed
EP-2877177-B1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN PF MEDICAMENT (FR) 2016-10-26 — — EP disclosed
EP-2877177-B1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN PF MEDICAMENT (FR) 2016-10-26 — — EP disclosed
US-9428510-B2 Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk PIERRE FABRE MEDICAMENT (FR) 2016-08-30 — — US disclosed
US-9428510-B2 Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk PIERRE FABRE MEDICAMENT (FR) 2016-08-30 — — US disclosed
US-20130085144-A1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT PIERRE FABRE MEDICAMENT (FR) 2013-04-04 — — US disclosed
US-20130085144-A1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT PIERRE FABRE MEDICAMENT (FR) 2013-04-04 — — US disclosed
US-20130085144-A1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT PIERRE FABRE MEDICAMENT (FR) 2013-04-04 — — US disclosed
EP-2545037-A1 INHIBITORS OF PROTEIN KINASES Ingenium Pharmaceuticals GmbH (DE) 2013-01-16 — — EP disclosed
CN-102834380-A Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH 2012-12-19 — — CN disclosed
WO-2012101239-A1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT PIERRE FABRE MEDICAMENT (FR) 2012-08-02 — — WO disclosed
WO-2012101239-A1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT PIERRE FABRE MEDICAMENT (FR) 2012-08-02 — — WO disclosed
US-20110224225-A1 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2011-09-15 — — US disclosed
WO-2011110612-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2011-09-15 — — WO disclosed
EP-0011092-A1 Alpha-aminophenylacetic acid derivatives for use in the treatment of inflammations and novel alpha-aminophenylacetic acid derivatives BAYER AG (DE) 1980-05-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085144-A1 DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT MAP2K5, MAP2K2, MAP2K3 ITGB3 3912/4885ITGA2B 4377/4885NPC1 2189/4885
US-20110224225-A1 Inhibitors of protein kinases CDK1, CDK2, CDK3 ITGB3 2691/4885ITGA2B 2934/4885NPC1 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.